Synthon has secured funding under the European Union’s Operational Programme Technologies and Applications for Competitiveness (OP TAK) to support the further expansion of its oligonucleotide development capabilities in Blansko, Czech Republic.
Scroll
View
Swipe
Play
May 2026
Synthon receives EU grant to strengthen R&D capabilities in Blansko
The grant will contribute to strengthening Synthon’s investments in R&D infrastructure and advanced technology capabilities, supporting the company’s focus on complex generic medicines and differentiated product development.
Click Here to access the certificate
This investment is closely aligned with Synthon’s strategy to build deep scientific and technical capabilities across its European footprint. By expanding the oligonucleotides development capacity in Blansko, Synthon reinforces its ability to bring complex, affordable medicines to patients while supporting long-term competitiveness.
It also reflects a broader priority for the Europe pharmaceuticals industry. A resilient generics sector requires sustained investment in R&D and manufacturing capability to create industrial competitiveness. As an active member of Medicines for Europe, Synthon remains committed to furthering this agenda and to strengthening Europe’s role in ensuring a robust, high quality supply of affordable medicines.